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Abstract
Panton–Valentine leukocidin (PVL)-positive methicillin-resistant Staphylococcus aureus (MRSA) that are multi-locus sequence type clonal
complex 22 (CC22) comprise a signiﬁcant public health problem in the UK. In the present study we sought to determine the genetic
diversity, and the respective patient demographics, among 47 PVL-MRSA with a CC22 pulsotype that occurred sporadically or in clusters
in community and healthcare settings in eight of nine geographic regions in England and Wales between January 2005 and September
2007. Patient demographics and disease presentations were typical for PVL-S. aureus infections (mostly skin and soft tissue infections in
individuals <40 years old); one patient with community-acquired pneumonia died. Although the isolates were closely genotypically related
by spa typing and pulsed ﬁeld gel electrophoresis, at least two variant groups were suggested. PCR detections demonstrated that the
majority of the CC22 PVL-MRSA identiﬁed (n = 42; 89%) harboured SCCmecIVc, three had SCCmecIVd, one had SCCmecIV but was
non-subtypeable, and one isolate harboured SCCmecV. At least three different PVL-encoding phages were detected: UPVL, U108PVL and
an unidentiﬁed icosahedral phage. Agar dilution MIC determinations showed that the CC22 PVL-MRSA identiﬁed were typically resistant
to gentamicin and trimethoprim (43 of 47 isolates) and ciproﬂoxacin resistance was also noted in six isolates. In conclusion, the CC22
PVL-MRSA tested were geographically disseminated but highly genetically related. The observed variances in acquired elements (most
notably SCCmec and PVL-encoding phages) suggested that CC22 PVL-MRSA in England and Wales have evolved on multiple occasions.
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Introduction
Worldwide, community-associated methicillin-resistant Staphylo-
coccus aureus (CA-MRSA) have caused infections among previ-
ously healthy individuals, often with few or no traditional
healthcare-associated risk factors for MRSA [1]; however, this
situation is changing in some parts of the world at least [2].
Although the origins of many major MRSA lineages remain
poorly understood, it is apparent that MRSA have emerged
on numerous occasions [3]. CA-MRSA harbour Staphylococcus
cassette chromosome mec, (SCCmec) type IV (24 kb), V
(28 kb) or VII (41.3 kb) [4–8] and are typically susceptible to
more antibiotics than healthcare-associated MRSA (HA-
MRSA). Additionally, CA-MRSA can encode bi-component
toxin Panton–Valentine Leukocidin (PVL) via lysogeny of one
of several icosahedral or elongated head shape temperate
PVL-encoding bacteriophages: USa2958, USa2mw, UPVL,
U108PVL, USLT and USa2USA [10,11]. Although MRSA with
PVL are typically associated with pyogenic skin and soft tissue
infections (SSTI) [12] they can cause life threatening disease,
most notably necrotizing pneumonia [13].
With the exception of the USA, the distribution of PVL-
MRSA strains is markedly polyclonal within a particular
region. In Europe, multilocus sequence type (MLST) ST80-
MRSA-SCCmecIV (European clone) has been associated with
severe disease and predominates among PVL-MRSA-related
infections, but other strains, such as ST8-SCCmecIVa
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(USA300) and ST30-SCCmecIVc (South West Paciﬁc clone),
also cause signiﬁcant morbidity and mortality [9,14]. In some
locales, other lineages of PVL-MRSA have been reported,
including MLST CC22 in Germany and Australia [15,16].
Recent analysis of PVL-MRSA referred to the national Staphy-
lococcus Reference Unit (SRU) for England showed that,
among polyclonal PVL-MRSA found in England, isolates of
MLST clonal complex (CC) 22 had caused signiﬁcant public
health problems [14]. In England and Wales, EMRSA-15
(ST22-IV) are dominant in the hospital setting, leading to sig-
niﬁcant public health implications [17]. This clone belongs to
the same MLST CC as the PVL-positive strains reported in
this study. Here we examined the molecular epidemiology of
CC22 PVL-MRSA from across England to better understand
the genetic variability within the lineage.
Materials and Methods
Bacterial isolates
The Health Protection Agency’s SRU performs epidemiologi-
cal typing and investigation of Staphylococcus isolates. Forty-
seven sporadic and cluster-associated PVL-positive MRSA
with a CC22-like pulsed-ﬁeld gel electrophoresis (PFGE)
pulsotype identiﬁed by the SRU between January 2005 and
September 2007 were included. The isolates were referred
from 21 centres across eight of nine regions of England and
Wales designated by the Health Protection Agency (http://
www.hpa.org.uk/HPA/ProductsServices/InfectiousDiseases/
RegionalMicrobiologyNetwork/), and were selected to maxi-
mize phenotypic and genotypic diversity.
Antibiotic susceptibility testing
MICs were determined by E-test (AB Biodisk, Solna, Sweden)
or agar dilution using Iso-Sensitest agar (Oxoid, Basingstoke,
UK), according to the latest British Society for Antimicrobial
Chemotherapy methods [18]. The antimicrobials tested were
penicillin, cefoxitin, oxacillin, methicillin, chloramphenicol, lin-
ezolid, sulphamethoxazole, trimethoprim, amikacin, tobra-
mycin, gentamicin, ciproﬂoxacin, erythromycin, clindamycin,
rifampicin, tetracycline, minocycline, doxycycline, tigecycline,
daptomycin, quinupristin-dalfopristin, vancomycin, teicoplanin,
fusidic acid and mupirocin. Isolates resistant to erythromycin
but sensitive to clindamycin were tested for inducible clinda-
mycin resistance (D-zone test) [19].
Toxin gene proﬁling and agr, SCCmec and ccr typing
Multiplex PCRs were used to detect 14 S. aureus toxin genes:
staphylococcal enterotoxin genes sea, seb, sec, sed and see
(reaction 1) [20]; seg, seh, sei and sej (reaction 2) [21]; toxic
shock syndrome toxin gene (tst) and exfoliatin toxin genes
eta and etb (reaction 3) [20]; and etd and lukS-PV lukF-PV
(reaction 4) [12,22] (enterotoxin L was not tested). The agr
allotype [23], SCCmec cassette and ccr allotype of each
CC22-like PVL-MRSA were determined by PCR [7,23–26].
DNA sequence-based typing and PFGE
Sequence typing of the spa gene repeat region (n = 47) and
MLST (n = 7) was performed as described previously [27,28].
BioNumerics (Applied Maths, Ghent, Belgium) was used to
analyse spa and MLST types by comparison with online data-
bases available at http://www.ridom.de/ and http://www.
mlst.net/ respectively. Banding patterns produced by SmaI
PFGE of chromosomal DNA [29] were also analysed using
BioNumerics to produce dendrograms via the unweighted-pair
group method (1% optimization and 1.9% position tolerance).
Phage characterization
Eight PCRs were performed to detect ﬁve of the PVL-encod-
ing phages (USa2958, USa2mw, UPVL, U108PVL and USLT)
[11]. Two PCRs were designed to identify the carriage of
two morphologically distinct phages by targeting genes
encoding icosahedral or elongated head shape. Two further
PCRs linked these morphologies to the PVL genes and the
remaining PCRs classiﬁed individual PVL phages [11]. Phages
that were not identiﬁable by these extended characterization
PCRs, but were positive for the icosahedral head type, were
described as being unknown icosahedral phages. PCR prod-
ucts were visualized on 1.5% agarose gels including 0.4 mg/L
ethidium bromide.
Results
The patient demographics and disease presentations for the
47 affected individuals with CC22 PVL-MRSA were typical for
PVL-MRSA [1] (Table 1). Four patients presented with upper
respiratory tract infection and one with bacteraemia
(Table 1). In addition, one patient presented with community-
onset pneumonia and subsequently died.
Overall, the isolates tested were all susceptible to linezolid,
clindamycin, rifampicin, doxycycline, tigecycline, daptomycin,
quinupristin-dalfopristin and vancomycin, and had variable lev-
els of resistance to oxacillin (MIC: 16 to >128 mg/L). All iso-
lates were accessory gene regulator type I and were indicated
as being highly genetically related with a minimum of 84.5%
similarity by PFGE (Fig. 1). One major PFGE group was identi-
ﬁed showing limited banding changes resulting in sub-groups A
and B (Fig. 1) and comprised 24 and 12 isolates, respectively
(Fig. 1). Thirty-four (72%) of the 47 isolates were spa type
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t005 or closely related and all of seven isolates selected to
represent the maximal genetic diversity within the isolate set
were conﬁrmed as ST22. Forty-six isolates harboured SCCme-
cIV (ccra2) (predominantly SCCmecIVc, n = 42) and all isolates
harboured either UPVL, U108PVL or an unknown icosahedral
phage (suggesting a PVL phage that is not detectable by the
current PCRs) (Fig. 1).
All 24 PFGE sub-group A isolates harboured the same
toxin genes and SCCmecIVc, and were highly related by spa
type; the only detected difference was one single-nucleotide
polymorphism (Fig. 1). At least three different PVL-encoding
phages were identiﬁed in this group: UPVL phage (n = 16),
U108PVL (n = 4) or unknown icosahedral phage (n = 5). All
sub-group A isolates were resistant to oxacillin, trimetho-
prim, gentamicin and tobramycin (Fig. 1), in accordance with
a previous study that identiﬁed mecA, aacA-aphD, aadD and
dfrA in CC22 PVL-MRSA [30]; further variable resistance(s)
were detected in some isolates (Fig. 1). All 12 PFGE sub-
group B isolates harboured SCCmecIVc and the same toxin
genes (Fig. 1); eleven had the same spa types (t005 and
t852). One isolate (t1516) had six repeat unit differences
compared to t005. The sub-group B isolates harboured
either UPVL (n = 10) or U108PVL (n = 2). All isolates in
sub-group B were resistant to oxacillin, gentamicin and tob-
ramycin; resistance to ﬂuoroquinolones macrolides and ami-
kacin was variable (Fig. 1). By PFGE and other methods, the
greatest genetic variability was apparent among the 11
remaining isolates; three different PVL-encoding phages were
detected; ﬁve isolates had SCCmecIVc, four had SCCmecIVd,
one had SCCmecIV that was not sub-typeable, and one had
SCCmecV (Fig. 1). The four isolates with SCCmecIVd
encoded enterotoxin C, in addition to the core pattern of
enterotoxins G, I and PVL, were spa t005 (n = 1), t849
(n = 1) and t1790 (n = 2), and were resistant to oxacillin
and fusidic acid; one isolate was also resistant to amikacin,
gentamicin and tobramycin. As observed among other sub-
groupings (above), the lysogenized PVL-encoding phages
varied among the SCCmecIVd-positive isolates.
Discussion
Subsequent to 2004, the SRU has observed the emergence
of a PVL-positive MRSA clone belonging to CC22 [14].
Occasional reports of ST22 PVL-MRSA in Germany and,
more recently, Australia [15,16] indicate their localized
emergence elsewhere, which also correlates with the pres-
ence of EMRSA-15 in these areas. In the present study, our
data show that the CC22 PVL-MRSA isolates studied com-
prised PFGE variant sub-groups (A and B) and 11 less clo-
sely-related isolates. The intra- and inter-group diversity in
the combinations of PVL-encoding phage and the SCCmec
type or subtype could suggest CC22 PVL-MRSA have
emerged on multiple occasions.
Consideration of the structure of the SCCmecIVc and IVd
cassettes found in 45 of the 47 isolates tested suggest that
insertion/deletion events could cause inter-conversion
between SCCmecIVc and IVd variants; however, the existence
of multiple differences between them [25] favours the scenario
that the different SCCmecIV subtypes represent independent
SCCmec acquisition events and different instances of the evo-
lution of ST22-PVL-MRSA (Fig. 2). The PVL status of MRSA
belonging to CC22 has been documented, although the distri-
bution of PVL-encoding phages within many populations of
S. aureus, including CC22 MRSA, has not been mapped [31].
At least three variant PVL-encoding phages were detected
among CC22-PVL-MRSA. The UPVL and U108PVL phage
genomes are highly conserved and, as observed by Otter et al.
[32], delineation between these variant phages may be ham-
pered by polymorphisms in the primer binding sites for the
detection of these two phages. Likewise, it cannot be ruled
out that the exchange of (or recombination between) PVL
phages in otherwise closely-related isolates of the same lineage
may have occurred. Notwithstanding, we have mapped the
PVL encoding phages within apparently closely-related isolates
and have identiﬁed the same phages in CC22 MRSA and methi-
cillin-sensitive S. aureus (MSSA) (data not shown), suggesting
the PVL-encoding phages were acquired prior to SCCmec
(Fig. 2). The presence of the same phages in isolates with
TABLE 1. Patient demographic data with disease pathology
associated with 47 Panton–Valentine leukocidin-positive
methicillin-resistant Staphylococcus aureus presumptively















Skin and soft tissue infections 17
Community-acquired pneumonia 1
Upper respiratory tract infection 4
Bacteraemia 1
Colonization 20
Clinical data not available 4
Total 47
Age/gender data were not available for three patients.
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different SCCmec types also supports this hypothesis, further
upholding the notion that the CC22 PVL-MRSA circulating in
the UK [14] have evolved on multiple occasions (Fig. 2).
Although EMRSA-15 (the predominant HA-MRSA in the
UK) also belongs to CC22, it has a different epidemiological
proﬁle; it is commonly associated with wound infections and
bacteraemia in elderly or severely ill hospitalized patients.
Although the acquisition of PVL by EMRSA-15 would increase
the virulence of a clone that is already highly transmissible and
poses a signiﬁcant public health concern, there are clear
genetic differences between these two lineages. Ciproﬂoxacin
and erythromycin resistance, t032 (or related) spa type and
carriage of SCCmecIVh are common traits among EMRSA-15
but differ from the CC22-PVL-MRSA investigated in the pres-
ent study (Fig. 2). A detailed study of the population structure
of EMRSA-15 would provide further evidence to the evolu-
tionary relationship between these two distinct groups of iso-
lates. Collectively, the data obtained suggest that PVL
positive-MRSA belonging to CC22 that have been investigated
here have emerged from PVL-positive MSSA on multiple occa-
sions, rather than from EMRSA-15 acquiring PVL [17,25,33].
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PFGE PFGE spa PVL Phage Antibiotic resistances SCCmec Toxin genes 
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL ERY, TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL ERY, TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL CIP, TMP, GEN, TOB IVc seg, sei , luk-PV
t852 a ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL MFX, ERY, TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Ɏ108PVL ERY, TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Ɏ108PVL ERY, AMI*, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL ERY, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t1516 a ɎPVL CIP, TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL MUP,ERY, TMP, GEN, TOB IVc seg, sei , luk-PV
t005 Ɏ108PVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Icosahedral  TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005a ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL CIP, TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL CIP, MFX, ERY,  TMP, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL CIP, MFX, ERY,  TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, GEN, TOB IVc seg, sei , luk-PV
t005 Icosahedral  TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Icosahedral  TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Ɏ108PVL TMP, GEN, TOB IVc seg, sei , luk-PV
t005 Ɏ108PVL TMP, AMI*,GEN, TOB, TET IVc seg, sei , luk-PV
t005 Ɏ108PVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Icosahedral  TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 Icosahedral  TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t852 ɎPVL CIP, MFX, ERY, TMP, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t005 ɎPVL CIP, MFX, TMP, GEN, TOB IVc seg, sei , luk-PV
t2816 a ɎPVL MFX, TMP, AMI*, GEN, TOB IVc seg, sei , luk-PV
t1790 ɎPVL CIP, MFX, ERY,  FUS IVd seg, sei , luk-PV,  sec 
t849 a Ɏ108PVL FUS IVd seg, sei , luk-PV,  sec 
t1790 a ɎPVL FUS IVd seg, sei , luk-PV,  sec 
t005 Ɏ108PVL FUS IVc seg, sei , luk-PV,  sec 
t005 Icosahedral TMP, GEN, TOB IV-NT* seg, sei , luk-PV







FIG. 1. Molecular characterization of clonal complex 22 (CC22)-like Panton–Valentine leukocidin (PVL)-positive methicillin-resistant Staphylococ-
cus aureus (MRSA). All isolates were tested for staphylococcal enterotoxins A–E (sea-e), and G–J (seg-j), toxic shock syndrome toxin-1 (tst),
exfoliative toxins A, B and D (eta, etb and etd), and PVL toxin (lukS-PV lukF-PV); all were positive for seg, sei and luk-PV. Antibiotic susceptibilities
were determined for penicillin, cefoxitin, oxacillin, methicillin, chloramphenicol, linezolid, sulphamethoxazole, trimethoprim, amikacin, tobramycin,
gentamicin, ciproﬂoxacin, erythromycin, fusidic acid, clindamycin, rifampicin, teicoplanin, doxycycline, tetracycline, tigecycline, minocycline dapto-
mycin, quinupristin-dalfopristin, vancomycin and mupirocin. SCCmec cassette type was determined by PCR. aIsolates selected for multilocus
sequence typing (n = 7). AMI*, Not susceptible to amikacin; IVd*, typed by Okuma et. al. [24], IV-NT*, not subtypeable by the PCR scheme
described by Milheirico et. al. [25] or Okuma et. al. [24]. Dendrogram generated using BioNumerics software showing cluster analysis of 47
CC22 PVL-MRSA based on pulsed ﬁeld gel electrophoresis, with 1% optimization and 1.9% position tolerance.
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